May 15, 2020 / 12:21 PM / 14 days ago

U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer

May 15 (Reuters) - The U.S. Food and Drug Administration declined to approve Blueprint Medicines Corp's therapy for previously treated patients with a type of cancer that affects the stomach and small intestine, the drugmaker said on Friday.

The therapy, Ayvakit, had previously been approved as the first treatment for a small subset of patients with a mutation of the cancer called gastrointestinal stromal tumor. ( (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Amy Caren Daniel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below